20181107 SITC Joint BioInvent Transgene EN
Category: 2018
NEC and Transgene announce a collaboration in the field of individualized cancer immunotherapy, leveraging NEC’s AI and Transgene’s myvac™ platform
Press Release NEC- Transgene EN
€26.6 million in cash and cash equivalents as of September 30, 2018
20181025 PR Q3-2018 EN
First Patient Dosed in a Phase 1/2 Trial of Transgene’s Oncolytic Virus TG6002 Administered Intravenously in Patients with Advanced Gastrointestinal Tumors
20181017 PR TG6002 US
Transgene to Present Positive Results from Phase 1b Trial of TG1050 in Patients with Chronic Hepatitis B at Upcoming AASLD Liver Meeting 2018
20181010 AASLD Abstract Poster EN
Transgene to Present its Viral Vector Expertise at the Society for Immunotherapy of Cancer Conference
20181001 SITC Poster VEN
Transgene unveils myvac™, an individualized immunotherapy against solid tumors
20180924 MyVac EN
Transgene Presents 2018 Half-Year Results and Business Update
20180919 H1 2018 RESULTS EN
Transgene Announces Upcoming Investor Meetings
20180903 PR financial agenda H2 18
Transgene completes the sale of the Greater China rights of TG6002 and TG1050 to Tasly Biopharmaceuticals for $48 million in newly-issued shares
180820 – TG Tasly Closing EN
